- Home
- OPT vs UFCS Comparison
OPT vs UFCS Comparison
Compare OPT & UFCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- UFCS
- Stock Information
- Founded
- OPT 1984
- UFCS 1946
- Country
- OPT Australia
- UFCS United States
- Employees
- OPT N/A
- UFCS N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- UFCS Property-Casualty Insurers
- Sector
- OPT Health Care
- UFCS Finance
- Exchange
- OPT Nasdaq
- UFCS Nasdaq
- Market Cap
- OPT 767.9M
- UFCS 642.7M
- IPO Year
- OPT 2020
- UFCS N/A
- Fundamental
- Price
- OPT $3.24
- UFCS $25.42
- Analyst Decision
- OPT Strong Buy
- UFCS Sell
- Analyst Count
- OPT 1
- UFCS 1
- Target Price
- OPT $12.00
- UFCS $19.00
- AVG Volume (30 Days)
- OPT 39.0K
- UFCS 106.7K
- Earning Date
- OPT 08-30-2024
- UFCS 11-05-2024
- Dividend Yield
- OPT N/A
- UFCS 2.52%
- EPS Growth
- OPT N/A
- UFCS N/A
- EPS
- OPT N/A
- UFCS 1.94
- Revenue
- OPT $261,859.00
- UFCS $1,207,451,000.00
- Revenue This Year
- OPT N/A
- UFCS N/A
- Revenue Next Year
- OPT $46,864.64
- UFCS $9.19
- P/E Ratio
- OPT N/A
- UFCS $13.09
- Revenue Growth
- OPT N/A
- UFCS 10.95
- 52 Week Low
- OPT $1.79
- UFCS $18.04
- 52 Week High
- OPT $5.45
- UFCS $25.88
- Technical
- Relative Strength Index (RSI)
- OPT 27.29
- UFCS 72.31
- Support Level
- OPT $4.02
- UFCS $24.62
- Resistance Level
- OPT $4.18
- UFCS $25.88
- Average True Range (ATR)
- OPT 0.22
- UFCS 0.83
- MACD
- OPT -0.13
- UFCS 0.49
- Stochastic Oscillator
- OPT 6.85
- UFCS 92.98
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.